Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report

On September 27‐28, 2018 the Food and Drug Administration (FDA) and the Critical Path Institute's Transplant Therapeutics Consortium convened a public workshop titled "Evidence‐Based Treatment Decisions in Transplantation: The Right Dose & Regimen for the Right Patient/Individualized T...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2020-06, Vol.20 (6), p.1495-1502
Hauptverfasser:	Mannon, Roslyn B., Morris, Randall E., Abecassis, Michael, Axelrod, David, Bala, Shukal, Friedman, Gary S., Heeger, Peter S., Lentine, Krista L., Loupy, Alexandre, Murphy, Barbara, Nickerson, Peter, Sarwal, Minnie, O'Doherty, Inish, Spear, Nicole, Karpen, Stephen R.
Format:	Artikel
Sprache:	eng
Schlagworte:	biomarker Biomarkers clinical trial design Clinical trials Critical path Drug Development Humans Immune response immunosuppressant Immunosuppressive agents Immunosuppressive Agents - therapeutic use Kidney Transplantation kidney transplantation/ nephrology Kidney transplants off‐label drug use Organ Transplantation Patients Pharmaceutical industry Risk assessment translational research/science Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!